Effect of 12 mg vs 6 mg of dexamethasone on the number of days alive without life support in adults with COVID-19 and severe hypoxemia: the COVID STEROID 2 randomized trial.
作者信息
Durr Kevin M, Hendin Ariel, Perry Jeffrey J
机构信息
Department of Emergency Medicine, The Ottawa Hospital, University of Ottawa, Ottawa, ON, Canada.
Ottawa Hospital Research Institute, Ottawa, ON, Canada.
出版信息
CJEM. 2022 Apr;24(3):266-267. doi: 10.1007/s43678-022-00293-1. Epub 2022 Mar 29.
Abstract
摘要
相似文献
1
Effect of 12 mg vs 6 mg of dexamethasone on the number of days alive without life support in adults with COVID-19 and severe hypoxemia: the COVID STEROID 2 randomized trial.
CJEM. 2022 Apr;24(3):266-267. doi: 10.1007/s43678-022-00293-1. Epub 2022 Mar 29.
2
Effect of 12 mg vs 6 mg of Dexamethasone on the Number of Days Alive Without Life Support in Adults With COVID-19 and Severe Hypoxemia: The COVID STEROID 2 Randomized Trial.地塞米松 12 毫克与 6 毫克对 COVID-19 合并严重低氧血症成人患者存活无生命支持天数的影响：COVID 类固醇 2 随机试验。
JAMA. 2021 Nov 9;326(18):1807-1817. doi: 10.1001/jama.2021.18295.
3
In COVID-19 with hypoxemia, 12 vs. 6 mg/d of dexamethasone did not increase days alive without life support.在低氧血症的 COVID-19 患者中，12 毫克/天与 6 毫克/天的地塞米松治疗并未增加无需生命支持的存活天数。
Ann Intern Med. 2022 Mar;175(3):JC33. doi: 10.7326/J22-0001. Epub 2022 Mar 1.
4
Dexamethasone and Number of Days Alive Without Life Support in Adults With COVID-19 and Severe Hypoxemia-Reply.地塞米松与新冠病毒肺炎合并严重低氧血症成人患者无生命支持存活天数——回复
JAMA. 2022 Feb 15;327(7):683. doi: 10.1001/jama.2021.24535.
5
Dexamethasone and Number of Days Alive Without Life Support in Adults With COVID-19 and Severe Hypoxemia.地塞米松与COVID-19合并严重低氧血症成人患者无生命支持存活天数的关系
JAMA. 2022 Feb 15;327(7):682. doi: 10.1001/jama.2021.24522.
6
Dexamethasone and Number of Days Alive Without Life Support in Adults With COVID-19 and Severe Hypoxemia.地塞米松与新冠病毒肺炎合并严重低氧血症成年患者无生命支持存活天数
JAMA. 2022 Feb 15;327(7):682. doi: 10.1001/jama.2021.24525.
7
Dexamethasone and Number of Days Alive Without Life Support in Adults With COVID-19 and Severe Hypoxemia.地塞米松与新冠病毒肺炎合并严重低氧血症成年患者无生命支持存活天数
JAMA. 2022 Feb 15;327(7):682-683. doi: 10.1001/jama.2021.24532.
8
Dexamethasone 12 mg versus 6 mg for patients with COVID-19 and severe hypoxaemia: a pre-planned, secondary Bayesian analysis of the COVID STEROID 2 trial.地塞米松 12 毫克对比 6 毫克治疗 COVID-19 伴严重低氧血症患者：COVID-STEROID 2 试验的预先计划的二次贝叶斯分析。
Intensive Care Med. 2022 Jan;48(1):45-55. doi: 10.1007/s00134-021-06573-1. Epub 2021 Nov 10.
9
Heterogeneous treatment effects of dexamethasone 12 mg versus 6 mg in patients with COVID-19 and severe hypoxaemia-Post hoc exploratory analyses of the COVID STEROID 2 trial.地塞米松 12 毫克与 6 毫克治疗 COVID-19 伴严重低氧血症患者的疗效差异：COVID 类固醇 2 试验的事后探索性分析。
Acta Anaesthesiol Scand. 2023 Feb;67(2):195-205. doi: 10.1111/aas.14167. Epub 2022 Nov 8.
10
Heterogeneity of treatment effect of higher dose dexamethasone by geographic region (Europe vs. India) in patients with COVID-19 and severe hypoxemia - a evaluation of the COVID STEROID 2 trial.新型冠状病毒肺炎（COVID-19）合并严重低氧血症患者中，高剂量地塞米松治疗效果在不同地理区域（欧洲与印度）的异质性——COVID STEROID 2试验评估
Lancet Reg Health Southeast Asia. 2023 Oct 4;20:100293. doi: 10.1016/j.lansea.2023.100293. eCollection 2024 Jan.
引用本文的文献
1
Associations between corticosteroid dosage and clinical outcomes in patients with hypoxemic COVID-19 pneumonia: A retrospective cohort study.低氧血症 COVID-19 肺炎患者皮质类固醇剂量与临床结局的关联：一项回顾性队列研究。
PLoS One. 2024 Sep 6;19(9):e0308069. doi: 10.1371/journal.pone.0308069. eCollection 2024.
2
Severe COVID-19: Drugs and Clinical Trials.重症新型冠状病毒肺炎：药物与临床试验
J Clin Med. 2023 Apr 16;12(8):2893. doi: 10.3390/jcm12082893.
本文引用的文献
1
Dexamethasone 12 mg versus 6 mg for patients with COVID-19 and severe hypoxaemia: a pre-planned, secondary Bayesian analysis of the COVID STEROID 2 trial.地塞米松 12 毫克对比 6 毫克治疗 COVID-19 伴严重低氧血症患者：COVID-STEROID 2 试验的预先计划的二次贝叶斯分析。
Intensive Care Med. 2022 Jan;48(1):45-55. doi: 10.1007/s00134-021-06573-1. Epub 2021 Nov 10.
2
Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19: The CoDEX Randomized Clinical Trial.地塞米松对中重度 COVID-19 相关急性呼吸窘迫综合征患者存活天数和无呼吸机天数的影响：CoDEX 随机临床试验。
JAMA. 2020 Oct 6;324(13):1307-1316. doi: 10.1001/jama.2020.17021.
3
Dexamethasone in Hospitalized Patients with Covid-19.地塞米松在 COVID-19 住院患者中的应用。
N Engl J Med. 2021 Feb 25;384(8):693-704. doi: 10.1056/NEJMoa2021436. Epub 2020 Jul 17.
Zotero 插件